BioScrip (NASDAQ:BIOS) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.
A number of other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. Canaccord Genuity assumed coverage on shares of BioScrip in a research report on Wednesday, December 12th. They set a “buy” rating and a $5.00 price target for the company. Lake Street Capital lifted their price target on shares of BioScrip from $4.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 7th. Finally, TheStreet upgraded shares of BioScrip from a “d+” rating to a “c-” rating in a report on Monday, November 26th. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $5.63.
Shares of BIOS opened at $3.49 on Friday. BioScrip has a 1-year low of $2.31 and a 1-year high of $4.14. The stock has a market cap of $458.38 million, a price-to-earnings ratio of -7.93 and a beta of 0.76.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Featured Story: Trading Stocks – What are percentage gainers?
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.